APONTIS PHARMA Revenue and Competitors
Estimated Revenue & Valuation
- APONTIS PHARMA's estimated annual revenue is currently $20.9M per year.
- APONTIS PHARMA's estimated revenue per employee is $201,000
Employee Data
- APONTIS PHARMA has 104 Employees.
- APONTIS PHARMA grew their employee count by 7% last year.
APONTIS PHARMA's People
| Name | Title | Email/Phone |
|---|
APONTIS PHARMA Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is APONTIS PHARMA?
APONTIS PHARMA is a pharmaceutical company focused on the commercialization of innovative pharmaceutical products to General Practitioners (GPs) and Internal Medicine Specialists in Germany. 
APONTIS PHARMA emerged in 2018 as a spin-off from a global pharmaceutical company UCB. APONTIS PHARMA builds on its long-standing UCB's and Schwarz Pharma's heritage.
keywords:N/A
N/A
Total Funding
104
Number of Employees
$20.9M
Revenue (est)
7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
APONTIS PHARMA News
DGAP-News: APONTIS PHARMA: START-Studie in wissenschaftlicher Publikation veröffentlicht - Kostenred.. Finanzen CH
APONTIS PHARMA: START study published in scientific journal - Cost reduction in the treatment of cardiovascular patients by Single Pill therapy Yahoo Finance
Paragon-backed Apontis Pharma announces IPO intention Unquote
Other Companies in Monheim am Rhein
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $18.9M | 122 | 24% | N/A |
#2 | $59.4M | 200 | 16% | N/A |
#3 | $56.3M | 209 | 61% | N/A |
#4 | $3.5M | 347 | 19% | N/A |
#5 | $3.5M | 406 | 19% | N/A |